Objective: The goal of this study was to explore the role of bradykinins and bradykinin 1 receptor (B1R) in murine lupus nephritis.
Methods: C57BL/6 and MRL/lpr mice were compared for renal expression of B1R and B2R by western blot and immunohistochemistry. MRL/lpr lupus-prone mice were administered the B1R antagonist, SSR240612 for 12 weeks, and monitored for blood pressure, proteinuria, renal function, and serum autoantibodies.
Results: Renal B1R:B2R ratios were significantly upregulated in MRL/lpr mice compared with B6 controls. B1R blockade ameliorated renal pathology lesions, proteinuria, and blood pressure, accompanied by lower serum IgG and anti-dsDNA autoantibody levels, reduced splenic marginal zone B cells and CD4 T cells, and renal infiltrating CD4 T cells, macrophages, and neutrophils. Both urine and renal CCL2 and CCL5 chemokines were also decreased in the B1R blocked MRL/lpr mice.
Conclusion: Bradykinin receptor B1R blockade ameliorates both systemic immunity and renal inflammation possibly by inhibiting multiple chemokines and renal immune cell infiltration. B1R blockade may be particularly attractive in subjects with concomitant lupus nephritis and hypertension.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325757 | PMC |
| http://dx.doi.org/10.1186/s13075-018-1774-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neurochemical mechanism of muscular pain: Insight from the study on delayed onset muscle soreness.
J Physiol Sci
January 2025
Department of Physical Therapy, Faculty of Rehabilitation, Niigata University of Health and Welfare, 950-3198, Niigata, Japan; Institute for Human Movement and Medical Sciences (IHMMS), Niigata University of Health and Welfare, 950-3198, Niigata, Japan.
We reviewed fundamental studies on muscular pain, encompassing the characteristics of primary afferent fibers and neurons, spinal and thalamic projections, several muscular pain models, and possible neurochemical mechanisms of muscle pain. Most parts of this review were based on data obtained from animal experiments, and some researches on humans were also introduced. We focused on delayed-onset muscle soreness (DOMS) induced by lengthening contractions (LC), suitable for studying myofascial pain syndromes.
View Article and Find Full Text PDFInhibition of mPFC norepinephrine improved chronic post-thoracotomy pain in adult rats.
Ann Med
December 2025
Department of Anesthesiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Background: Chronic post-thoracotomy pain (CPTP) is characterized by high incidence, long duration, and severity of pain. Medial prefrontal cortex (mPFC) is a brain region closely associated with chronic pain, and norepinephrine is involved in pain regulation. But the role of mPFC norepinephrine in CPTP and its possible mechanism is unclear.
View Article and Find Full Text PDFSARS-CoV-2 Productively Infects Human Hepatocytes and Induces Cell Death.
J Med Virol
January 2025
Institute of Virology, Technical University of Munich/Helmholtz Munich, Munich, Germany.
Article Synopsis
- SARS-CoV-2 can infect liver cells (hepatocytes), leading to elevated liver enzymes and more severe disease in those with pre-existing liver conditions.
- The study shows that the virus replicates and spreads in hepatocytes, with infection being dependent on two specific proteins, ACE2 and TMPRSS2, which are found on the liver cells.
- Infection causes rapid liver cell death, with the Omicron variant causing quicker but less extensive damage compared to other strains, as seen in both human liver cells and infected mice.
Recombinant Human Tissue Kallikrein-1 for Treating Acute Ischemic Stroke and Preventing Recurrence.
Stroke
January 2025
Experimental Cardiovascular Medicine, University of Bristol, United Kingdom (P.R.M.).
Novel strategies are needed for the treatment of acute ischemic stroke when revascularization therapies are not clinically appropriate or are unsuccessful. rKLK1 (recombinant human tissue kallikrein-1), a bradykinin-producing enzyme, offers a promising potential solution. In animal studies of acute stroke, there is a marked 36-fold increase in bradykinin B2 receptor on brain endothelial cells of the ischemic region.
View Article and Find Full Text PDFInterplay between on-demand treatment trials for hereditary angioedema and treatment guidelines.
J Allergy Clin Immunol
December 2024
University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA. Electronic address:
Over the past two decades, guidelines for the on-demand treatment of hereditary angioedema (HAE) attacks have undergone significant evolution. Early treatment guidelines, such as the Canadian 2003 International Consensus Algorithm, often gated on-demand treatment by attack location and/or severity. Pivotal trials for on-demand injectable treatments (plasma-derived C1 esterase inhibitor [C1INH], icatibant, ecallantide [US only], recombinant C1INH), which were approved in the US and EU between 2008-2014, were designed accordingly.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!